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-23.78 vs. -19.71 in WHO-DAS-II (F24.5, p0.001), respectively. After discounting
the effect on anxiety reduction over time, the estimated PGB effect over UC in-
crease on both sleep disturbances and disability scores were still significant (g-
3.99, p0.001 and g-3.07, p0.001, respectively). Mediation analysis showed that
70% and 58% of the direct effect of PGB over, respectively, sleep disturbances and
disability remained after discounting the mediated effect of anxiety improvement.
CONCLUSIONS: Adding pregabalin to usual care produced better improvements in
sleep disturbances and disability related GAD symptoms in outpatients treated in
real world conditions. 70% and 58% of the total effect of PGB over usual care was
explained by its direct effect not mediated by improvements in anxiety symptoms.
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OBJECTIVES: Specific instruments are developed measuring HRQoL in children and
adolescents. Currently, these instruments are not applicable in health economic
studies as valuations for health states are lacking. The aim of the current study was
to compare the psychometric properties of a generic child-specific and a generic
preference based instrument in children and adolescents with ADHD. METHODS:
A questionnaire survey was performed among parents with a child diagnosed with
ADHD. Results on the proxy versions of the KIDSCREEN-10 and the EQ-5D were
used to compare the constructs describing HRQoL of the instruments and their
responsiveness to different health states. Principal Component Analaysis (PCA)
with varimax rotation was used for identifying factors underlying the constructs of
both instruments. A comparison was performed of the index scores on both instru-
ments between respondents with different stimulant medication profiles and dif-
ferent comorbidity profiles using Student’s t-tests. Additionally, Cohen’s effect
sizes were calculated for an indirect comparison of the instruments’ responsive-
ness and discriminating ability. RESULTS: Using the EQ-5D dimensions and the
items of the KIDSCREEN -10 the PCA identified 5 separate components of HRQoL. A
physical component and a mental component included a combination of EQ-5D
dimensions and KIDSCREEN-10 items. No associations of the EQ-5D dimensions
‘self-care’ and ‘usual activities’ and KIDSCREEN-10 items was found. Additionally,
no association was found of KIDSCREEN-10 items related to performance at school
and satisfaction with free time activities and EQ-5D dimensions. Scores of both
instruments differed significantly according to respondents’ treatment and comor-
bidity profile. Cohen’s effect sizes indicated comparable responsiveness and dis-
criminative ability of the instruments. CONCLUSIONS: The results highlight that
the two instruments measure different constructs of HRQoL. Despite this, the anal-
yses showed comparable responsiveness to different health states and discrimi-
native ability of the instruments. These results suggest that the KIDSCREEN and
the EQ-5D are complementary instruments.
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OBJECTIVES: Patient-reported outcomes (PROs) are widely used in mental health
research to assess treatment benefits for patients. The objective of this study is to
evaluate literature describing health-related quality of life (HR-QoL) PRO tools used
in schizophrenia, and to report level of validation of available instruments.
METHODS: A systematic search of the EMBASE, Pubmed and ISPOR conference
abstracts databases was conducted. No restrictions on date of submission or geo-
graphical region were applied. Conceptual framework, reliability (internal consis-
tency and reproducibility), validity (content validity and construct validity) and
sensitivity to change for the measures were evaluated. RESULTS: Fifiteen instru-
ments were identified (4 generic, 3 severe mental illness specific, 5 schizophrenia
specific and for 2 instruments it was not possible to retrieve this information).
Among generic questionnaires EQ-5D had the highest level of validity and a rea-
sonable level of sensitivity to change. Among severe mental illness specific ques-
tionnaires, The Tolerability And Quality Of Life Questionnaire (TOOL) showed high
validity, reliability and sensitivity. Subjective experience of antipsychotic drugs
was well-assessed with the Subjective Well-being under Neuroleptics Scale (SWN).
The validity of the SWN was acceptable and the tool included assessment of sub-
jective experience to evaluate differential effects of anti-psychotics and dose reg-
imens. Amongst the schizophrenia specific PROs to evaluate QoL, the quality Of
Life Questionnaire In Schizophrenia (S-QoL) was judged to have a high level of
validity and sensitivity to change and the quality of life measure for persons with
schizophrenia (QOLM-S), a 30-item scale, also showed internal reliability and con-
struct validity. CONCLUSIONS: Within schizophrenia, EQ-5D appears to have high
level of validity and sensitivity to change compared to other generic instruments.
Two disease specific instruments were considered as validated among which S-
QoL was the only one to show sensitivity to change. Our recommendation would be
to use EQ-5D or S-QoL in future studies.
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OBJECTIVES: To evaluate health-related quality of life (HRQOL) and its determi-
nants in Japanese patients with chronic schizophrenia on antipsychotic
polypharmacy. METHODS: The data were collected from an ongoing prospective
randomized comparative study entitled, “The clinical study to correct multiple and
large amount of administering to antipsychotic safely and effectively,” conducted
in Japan. The subjects were 133 Japanese patients diagnosed with schizophrenia.
Of these, 75 were evaluated once, while 49 and 9 were evaluated twice and three
times, respectively. Therefore, we were able to use data from a total of 200 evalu-
ations. The subjects’ mental status was assessed with the Manchester Scale (MS).
The severity of extrapyramidal side effects was assessed with the Drug-Induced
Extrapyramidal Symptoms Scale (DIEPSS), and the severity of autonomic side ef-
fects was assessed with the subscales extracted from the “Udvalg for Kliniske
Undersogelser(UKU).” HRQOL was evaluated using the EuroQOL (the EQ-5D and the
visual analogue scale, EQ-VAS). Independent determinants of HRQOL were identi-
fied using stepwise multiple regression analysis. RESULTS: The mean age (stan-
dard deviation) of the subjects was 56.4 (11.4). There were 54 females and 78 males.
The average disease duration was 29.2 (12.3) years. The mean utility score derived
from the EQ-5D of the total of 200 evaluations was 0.711 (0.211). The mean EQ-VAS
score was 0.632 (0.213). Independent determinants of reduced utility score were:
severity of “hallucinations” in the MS; “diarrhea” and “orthostatic dizziness” in the
UKU; severity of “gait” in the DIEPSS; and female gender.CONCLUSIONS:This is the
first report investigating the determinants of HRQOL in patients with schizophre-
nia in Japan. This report suggests that in addition to hallucinations, several side
effects induced by antipsychotics, such as diarrhea, postural hypotension, and
Parkinsonism, might play an important role in patients with schizophrenia.
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OBJECTIVES: To elicit the willingness to pay (WTP) of different stakeholders re-
garding different aspects of treatment of schizophrenia.METHODS:We conducted
a survey of 259 Swedes with a serious mental disorder, 263 relatives of individuals
suffering from a serious mental disorder and 528 people sampled from the general
population. We designed a discrete choice experiment (DCE) to determine respon-
dents’ WTP. Conditional logit was used to derive the WTP results. RESULTS: The
value of reducing the required frequency from every other week to once a month is
141 SEK per month for patients, 192 SEK per month for relatives, and 227 SEK per
month for the general population. The value of reducing the required frequency
from every other week to once every 3 months is 269 SEK per month for patients, 349
SEK per month for relatives, and 414 SEK per month for the general population.
Accompanying visits every 3 months with a consultation about general well-being
is worth 149 SEK per month for patients, 247 SEK per month for relatives, and 148
SEK per month for the general population. The value of being able to store medi-
cation outside a refrigerator at room temperature instead of in a refrigerator is 130
SEK per month for patients, 176 SEK per month for relatives, and 198 SEK per month
for the general population. CONCLUSIONS: There is a significant, positive willing-
ness to pay for reduced injection frequency (at doctors’ or cliniques), not having to
store drugs in refrigerator compared to storage at room temperature, and having
consultation about general well-being every three months.
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OBJECTIVES: Stigma and prejudice surrounding people with mental illnesses are a
major impediment that contributes to prevent them to access to health care. This
is the first part of a project that aims to assess impact of mental disorders stigma on
willingness to pay for health care. The first part of the project describes public
beliefs and attitudes about schizophrenia, major depression and psychotropic
drugs. METHODS: Three questionnaires were administered online to a represen-
tative sample of 2400 French people. 800 persons answered a questionnaire on
schizophrenia, 800 on major depression and 800 about psychotropic drugs. They
were asked to address a validated questionnaire. RESULTS:All 2400 questionnaires
were fully completed. 57.9% (resp. 35.3%) of people reported being not comfortable
in presence of a schizophrenic patient (resp. major depression), while 18.6% (resp.
39.0%) reported they did. More than 72.1% (resp. 80.9%) felt the need to help people
suffering from schizophrenia (resp. major depression), although 60.0% (resp. 16.3%)
think that such patients are strange, and 36.1% (resp. 14.5%) think they are danger-
ous. 9.1% agree with the fact that psychotropic treatment helps people to better
support the concerns of everyday life and 8.8% agree with taking these medicines
if the person suffers constantly of light mood swings. CONCLUSIONS: This study
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